Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
IMBA - Institut für Molekulare Biotechnologie GmbH currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active matters are distributed across 3 distinct art units and involve 3 distinct examiners. This distribution indicates a diversified prosecution strategy where the company is simultaneously advancing multiple technical projects or different aspects of a complex technology. The involvement of 3 separate art units suggests that the company's innovations span several specialized classifications within the biotechnology sector, requiring a broad management approach to handle different technical standards.
ZANNA MARIA BEHARRY is the busiest examiner, although they are responsible for only 1 pending office action. Because each of the 3 pending office actions is assigned to a different examiner, the company must navigate unique examination styles and sets of procedural requirements for every case. This lack of examiner overlap means that the outcomes in one matter may not necessarily predict the results in others, even within the same technology area. Practitioners must coordinate responses across 3 distinct examiners to ensure consistency in the company's overall intellectual property strategy while addressing the specific concerns of each individual official. This level of distribution across 3 distinct art units requires careful monitoring of diverse patent office requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260418 | BLASTOCYST-LIKE CELL AGGREGATE AND METHODS | MARTIN, PAUL C | 7d |
| 18558243 | CONTROLLED GENE EXPRESSION METHODS AND MEANS | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260418 | BLASTOCYST-LIKE CELL AGGREGATE AND METHODS | MARTIN, PAUL C | 7d |
| 18558243 | CONTROLLED GENE EXPRESSION METHODS AND MEANS | BEHARRY, ZANNA MARIA | — |
| 16608719 | BI- OR MULTI-DIFFERENTIATED ORGANOID | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1653 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558243 | CONTROLLED GENE EXPRESSION METHODS AND MEANS | BEHARRY, ZANNA MARIA | 1632 | §101§103§112 | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18260418 | BLASTOCYST-LIKE CELL AGGREGATE AND METHODS | MARTIN, PAUL C | 1653 | §103§112 | Non-Final OA | 7d | Pending | Jul 05, 2023 |
| 16608719 | BI- OR MULTI-DIFFERENTIATED ORGANOID | WANG, CHANG YU | 1675 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial